Salmon-derived bioactive peptides are short amino acid chains released from salmon protein that interact with specific biological receptors. This guide covers what the published research shows — from in-vitro receptor studies to human clinical research — and how ProGo® fits into the science.
What are the benefits of salmon peptides? Salmon-derived bioactive peptides are short amino acid chains from salmon protein hydrolysate that have been studied for their ability to support GLP-1 and GIP receptor activity (in in-vitro, cell-based research), appetite regulation, gut barrier health, and lean-muscle preservation through myostatin signaling. ProGo®, the salmon protein hydrolysate in triGLP, is a clinically studied ingredient holding FDA NDI status and 13 structure/function claims the FDA has not objected to. Individual results vary.
Salmon peptides — more precisely called salmon-derived bioactive peptides or salmon protein hydrolysate (SPH) — are short chains of amino acids produced by enzymatically breaking down salmon protein. This process, called hydrolysis, mimics what your digestive system does when it processes dietary protein: it cleaves the long protein chains into smaller fragments. Some of those fragments are inert, functioning simply as amino acid delivery vehicles. Others are biologically active — meaning they interact with specific receptors and signaling pathways in the body.
The term "bioactive" is what matters here. Not all fish-protein supplements contain bioactive peptide fractions in meaningful concentrations; most fish protein powders or generic omega-3 supplements are not the same thing. Marine peptides used as dietary supplement ingredients are produced through controlled enzymatic hydrolysis to concentrate specific short-chain sequences — typically two to twenty amino acids in length — that have identified biological activity at supplement doses.
Salmon, in particular, has attracted scientific interest because Atlantic salmon yields a rich profile of bioactive peptide fractions. The protein composition of Norwegian Atlantic salmon — raised in cold, clean waters with a distinct amino acid profile — produces hydrolysate fractions that have been studied for metabolic, gut, and muscle-related biological activity. Hofseth BioCare ASA, the Norwegian biotechnology company behind ProGo®, has built the ingredient around this specific salmon protein source.
For a broader context on how bioactive peptides support weight management, the parent pillar on this site covers the full mechanism landscape. This article focuses specifically on what the research shows about salmon-derived peptides and how ProGo® fits that science.
The research on salmon-derived bioactive peptides spans several biological areas. It is important to be precise about study types — in-vitro findings (cell-based laboratory research) and human clinical studies are not interchangeable. The science below is described with that distinction clearly maintained.
The most cited peer-reviewed study on ProGo®-relevant salmon peptides is: Currie et al., "Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors by Salmon Protein Hydrolysate-Derived Bioactive Peptides," indexed on PubMed/NCBI at PMC11595994.
This was an in-vitro (cell-based, laboratory) study — not a human clinical trial. The researchers exposed cell lines bearing GLP-1 and GIP receptors to fractions of salmon protein hydrolysate and measured receptor activation signals. The findings showed that the smallest peptide fractions from the salmon hydrolysate activated both GLP-1 and GIP receptors in the cell-based assay. The study identified which size fractions were most active and characterized the dose-response in the cell system.
What does this mean in plain language? GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating that signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar. GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone that supports insulin response and energy metabolism. The in-vitro study demonstrated that specific salmon peptide fractions can engage these receptor systems in a laboratory cell model. This is a meaningful first-step finding — it establishes the mechanism of interaction — but in-vitro findings do not by themselves guarantee specific outcomes in every person who takes a supplement. Human physiology involves many more variables than a cell assay.
The study provides the biological rationale for why salmon-derived bioactive peptides may support GLP-1- and GIP-related metabolic functions. It is the foundational science behind the structure/function claims the ingredient carries. You can learn more about how these pathways work in the guide to natural GLP-1 support.
Beyond the in-vitro work, a human clinical study has been conducted on the ProGo® salmon protein hydrolysate ingredient: a 42-day randomized, placebo-controlled study in overweight adults. This is a meaningful upgrade from cell-based research — a randomized controlled design in a human population over a six-week period provides a higher level of evidence for ingredient assessment.
Study details: the trial compared the ProGo® ingredient against placebo in a population of overweight adults, measuring outcomes over 42 days. The study describes what was observed in that specific population, at that specific dose, over that period. As with all ingredient clinical research, the findings describe the ingredient's behavior — they do not constitute a guarantee of any specific product outcome for any individual, and individual results vary.
This distinction matters: the clinical research was conducted on the ingredient (salmon protein hydrolysate / ProGo®) — it is accurate to say ProGo® is a clinically studied ingredient. It would not be accurate to claim the product itself is "clinically proven" for a specific weight-loss outcome in every user.
One of the most scientifically distinctive areas of ProGo® research involves myostatin and Activin A signaling. Myostatin is a protein that acts as a natural brake on muscle growth — it inhibits the formation of new muscle tissue. Research has explored whether certain salmon-derived bioactive peptide fractions may support the down-regulation of myostatin activity, which in turn could support lean-muscle maintenance during periods of caloric restriction or weight management.
This pathway matters specifically for people pursuing weight management: losing fat while preserving muscle mass is a well-established goal in nutrition science, and the myostatin angle is a biochemically plausible mechanism by which a food-derived peptide ingredient might support that balance. ProGo® carries structure/function claims related to lean-muscle preservation that the FDA has not objected to — a meaningful regulatory signal that the substantiation meets the legal standard for dietary supplement claims in the US.
For a deeper look at how this fits into fat loss vs. muscle preservation goals, see the guide to losing fat while keeping muscle.
A third biological area of interest for salmon-derived bioactive peptides is the GLP-2 pathway. GLP-2 (glucagon-like peptide-2) is a hormone that supports the integrity of the intestinal lining, promotes gut mucosal growth, and plays a role in nutrient absorption. Supplement ingredients that may support GLP-2 activity have attracted research interest for their potential role in gut barrier health — the structural integrity of the intestinal wall that separates the gut lumen from systemic circulation.
ProGo® carries structure/function claims related to gut health that the FDA has not objected to. The biological rationale for these claims connects to the peptide fractions' potential interaction with GLP-2 signaling pathways, as part of the broader receptor-activity landscape studied in the in-vitro research. For readers specifically interested in the gut health angle, the gut health supplement guide on this site covers the broader context.
Not all products marketed as "fish peptides for metabolism" or "marine peptide supplements" are the same. The salmon peptide benefits described in the research above are tied to specific peptide fractions from a specific source, produced and characterized by a specific manufacturing process. Generic fish collagen, omega-3 supplements, or uncharacterized "fish protein" powders are different products with different biological properties.
Here is what differentiates ProGo® from the broader category of marine protein supplements:
| Dimension | ProGo® Salmon Protein Hydrolysate | Generic Fish / Marine Protein Supplements |
|---|---|---|
| Source specificity | Norwegian Atlantic salmon, sustainably sourced, controlled hydrolysis process | Often unspecified species, geography, or production method |
| Peptide characterization | Specific bioactive fractions identified and studied for receptor activity | Typically whole protein or collagen; bioactive fraction content not characterized |
| Regulatory status (US) | FDA New Dietary Ingredient (NDI) notification, no objection; 13 structure/function claims | Generally regulated as dietary supplement; NDI and claim substantiation varies widely |
| Certifications | Non-GMO Project Verified, GMP, Kosher, Halal, HACCP, free from antibiotics/pesticides/BSE-TSE | Certifications vary; many lack third-party verification |
| Published peer-reviewed research | In-vitro GLP-1/GIP receptor study (Currie et al., PMC11595994) + 42-day human study | Limited or no ingredient-specific published research for most brands |
| Pathways studied | GLP-1, GIP, GLP-2 receptor activity; myostatin/Activin A signaling | Rarely studied for specific metabolic receptor activity |
This level of characterization is not typical in the supplement industry. The combination of a specific Norwegian salmon source, controlled enzymatic hydrolysis to produce identified bioactive fractions, published receptor-activity research, an FDA NDI notification, and a full certification stack is what makes ProGo® a differentiated ingredient — not just another marine protein supplement.
The "three pathways" that triGLP references correspond to three distinct metabolic signaling systems that salmon-derived bioactive peptides have been studied in relation to. Here is what each does:
GLP-1 (glucagon-like peptide-1) is produced by specialized cells in the small intestine in response to food intake. It acts on the brain's appetite-regulation centers to promote feelings of fullness, slows the rate at which food leaves the stomach (gastric emptying), and supports insulin release in a glucose-dependent manner — meaning it helps the body manage blood sugar in proportion to what was eaten. These are well-established functions supported by decades of research in nutritional physiology and metabolic medicine.
The in-vitro study by Currie et al. (PMC11595994) found that salmon protein hydrolysate fractions activated GLP-1 receptors in cell-based assays. This cell-based finding provides a mechanistic foundation for the structure/function claims ProGo® carries relating to appetite and metabolic signaling support. It does not mean every individual will experience a specific appetite change — human GLP-1 signaling involves many interacting variables beyond receptor binding.
GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, produced in the upper small intestine. It works in concert with GLP-1 to support insulin secretion after eating and plays a role in energy storage and fat metabolism. Research interest in GIP has accelerated significantly as scientists have explored dual GLP-1/GIP pathway interactions in metabolic health.
The Currie et al. in-vitro study found salmon peptide fractions activated GIP receptors in addition to GLP-1 receptors — a finding that is biologically relevant because dual incretin pathway activity represents a more complete metabolic signaling picture than GLP-1 alone. Again: this is cell-based research. The in-vitro finding establishes receptor-level interaction; it is one piece of a larger scientific picture.
GLP-2 (glucagon-like peptide-2) is structurally related to GLP-1 but acts on different target tissues. Its primary known functions are supporting the growth and repair of the intestinal lining (gut mucosa), maintaining gut barrier integrity, and regulating nutrient absorption. A healthy gut barrier is important for overall metabolic function — a compromised intestinal barrier has been associated in research with systemic inflammation and metabolic dysregulation.
ProGo® carries structure/function claims related to gut health that the FDA has not objected to, connected to this pathway. The gut health supplement guide on this site goes deeper on why gut barrier support matters in the context of metabolic health and weight management.
The myostatin pathway is arguably the most distinctive element of the ProGo® research story — and the one most often overlooked in general discussions of fish peptides for metabolism.
Myostatin (also known as growth differentiation factor 8, or GDF-8) is a protein produced by muscle cells that inhibits skeletal muscle growth. It acts as a natural brake on muscle development, maintaining a biological ceiling on how much muscle the body builds. Activin A is a related signaling molecule that also promotes muscle degradation through similar pathways.
Research interest in myostatin inhibition has been significant in both sports science and metabolic health contexts. In the context of weight management, preserving lean muscle mass during a caloric deficit is an important goal — muscle is metabolically active tissue that supports baseline energy expenditure. Losing muscle mass during weight loss can slow metabolism and make long-term weight maintenance more difficult.
ProGo® holds structure/function claims related to lean-muscle preservation, substantiated in part through research on the ingredient's interaction with myostatin and Activin A signaling. The FDA has not objected to these claims — a signal that the substantiation meets the regulatory standard for structure/function claim validity under US dietary supplement law.
This muscle-preservation angle is a meaningful differentiator for triGLP compared to supplements that focus solely on appetite or metabolic rate. Supporting lean-muscle maintenance during weight management is a distinct and complementary benefit pathway. For readers focused on this area, the guide to losing fat while keeping muscle covers the science in depth.
Not all salmon protein hydrolysates are equivalent, and the source specificity of ProGo® is scientifically and quality-assurance relevant. Hofseth BioCare ASA sources Norwegian Atlantic salmon — a specific species (Salmo salar) raised in Norwegian fjords and cold-water marine environments under strict aquaculture standards.
The relevance of source specificity for bioactive peptides is that the biological activity of peptide fractions depends on the amino acid composition and sequence of the parent protein, which varies by species, diet, and growing conditions. Salmon raised in different environments, fed different diets, or processed using different hydrolysis parameters will yield different peptide fraction profiles. The research on ProGo® was conducted on the specific ingredient produced by Hofseth BioCare's defined manufacturing process — not on a generic fish protein hydrolysate.
The Norwegian sourcing also intersects with the certification stack: the ingredient is certified free from antibiotics, pesticides, and BSE/TSE (bovine spongiform encephalopathy / transmissible spongiform encephalopathy), which are particularly relevant for supplement ingredients where contamination from farming inputs would undermine the quality and safety profile. Non-GMO Project Verification adds a further layer of independent auditing on the ingredient's production.
Hofseth BioCare ASA is a publicly traded Norwegian biotechnology company (Oslo Børs: HBC) whose business is built on the science and commercialization of salmon-derived bioactive ingredients. That institutional context — a dedicated ingredient company with public accountability and a published science track record — is a meaningful signal of ingredient credibility that generic supplement contract manufacturers typically cannot match.
ProGo® salmon protein hydrolysate is the active ingredient in triGLP, the flagship supplement product on this site. triGLP delivers the ingredient in a concentrated liquid drop format — taken sublingually (under the tongue) — rather than as a powder or capsule.
The sublingual format is designed for efficient absorption, bypassing the initial digestive processing that occurs with oral capsules or powders. ProGo® peptides are inherently small-chain amino acid sequences, which supports their absorption potential, but the specific dose-equivalence between the triGLP drops and the studied powder dose has not been independently established through a separate clinical study. ORYGN's formulation uses a concentrated extract; the research-substantiated doses in the published studies were for the powder/hydrolysate form.
triGLP is not a prescription medication. It is a dietary supplement. It does not require a prescription, is not administered by injection, and is not in the same regulatory or pharmacological category as prescription metabolic medications. Its role is to support the body's own GLP-1, GIP, GLP-2, and myostatin pathways through a food-derived, NDI-status ingredient — not to replicate or substitute for pharmaceutical-grade compounds.
Individual results vary. See footer for full disclaimer.
Two regulatory facts about ProGo® deserve clear explanation — not just as marketing signals, but because understanding what they actually mean helps you evaluate the ingredient honestly.
The FDA does not "approve" dietary supplements the way it approves pharmaceutical drugs. However, for ingredients introduced into the US dietary supplement market after 1994, manufacturers must submit a New Dietary Ingredient (NDI) notification to the FDA before marketing. The notification includes safety evidence based on the ingredient's history of use, manufacturing process, and available toxicological and compositional data.
The FDA reviews NDI notifications and may raise objections if it finds the safety substantiation inadequate. When an NDI notification receives no objection, that is a meaningful positive safety signal — the agency reviewed the submission and did not find grounds to challenge it. ProGo® holds FDA NDI status with no objection. This does not mean the FDA "approved" the product; it means the FDA reviewed the safety evidence and did not object to the ingredient's use as a dietary supplement.
Under US law, dietary supplement companies may make "structure/function claims" — statements that describe how a nutrient or ingredient supports normal body structures or functions — provided those claims are substantiated and truthful, and provided the product carries the required disclaimer that the claim has not been evaluated by the FDA and the product is not intended to diagnose, treat, cure, or prevent any disease.
ProGo® carries 13 structure/function claims that the FDA has not objected to. This means the manufacturer submitted the claims to the FDA (as required), and the FDA did not flag them as objectionable. This is not an FDA endorsement or approval — it is a structured regulatory interaction that validates the claims meet the legal standard for dietary supplement structure/function language.
These 13 claims cover the pathways discussed throughout this article: GLP-1 and GIP receptor support, gut barrier health, lean-muscle preservation, and related metabolic functions. They represent a substantiated claim base that most supplement ingredients — which often carry no structure/function claims, or carry unsubstantiated ones — do not have.
Salmon-derived bioactive peptides with the ProGo® profile are a well-characterized, certified, food-grade supplement ingredient. That said, honest discussion of salmon peptide benefits requires naming considerations that matter for specific individuals.
ProGo® is derived from Atlantic salmon — a fish. Individuals with known fish allergies, shellfish allergies, or broad seafood sensitivities must consult a healthcare provider before using any salmon-derived supplement. This is a hard stop, not a precautionary hedge.
If you are currently using prescription medications that affect appetite, blood sugar, insulin response, or weight — including prescription GLP-1 medications — you should not add any supplement affecting the same pathways without explicit guidance from your prescribing physician. This applies specifically to supplements studied for GLP-1 and GIP pathway activity.
Ingredients that support incretin pathway activity (GLP-1, GIP) may influence blood sugar regulation. Anyone managing a blood sugar condition with medication should involve their physician before adding any metabolic supplement.
As with all non-essential dietary supplements, use during pregnancy or while breastfeeding is not advised unless a healthcare provider specifically approves it. Insufficient safety data exists for these populations.
For a full discussion of safety considerations across the peptide supplement landscape, see the companion article on whether peptides are safe for weight loss.
Here is a direct synthesis of what the peer-reviewed science and regulatory record support for salmon-derived bioactive peptides like ProGo®:
ProGo® peptides represent a differentiated marine peptide ingredient with meaningful substantiation — not because the research guarantees any specific individual outcome, but because the depth and specificity of the research, the regulatory engagement, and the certification infrastructure set it apart from the majority of supplement ingredients that carry no comparable evidence base.
If you are evaluating triGLP as part of a metabolic health or weight management strategy, the honest starting point is understanding the ingredient's research profile clearly — what type of studies exist, what they found, and what they can and cannot claim. That is what this guide was written to provide. For the next step, visit the triGLP product page for full certification details and how to order.
triGLP is made with ProGo® — a clinically studied ingredient from Norwegian Atlantic salmon that supports GLP-1, GLP-2 & GIP pathways and lean-muscle preservation. Not a prescription. Not an injection.
Shop triGLP →Individual results vary. See footer for full disclaimer.
Salmon-derived bioactive peptides are short chains of amino acids produced by enzymatically breaking down salmon protein — a process called hydrolysis. The result is a salmon protein hydrolysate containing specific small-chain peptide sequences that have identified biological activity. ProGo®, produced by Hofseth BioCare ASA from Norwegian Atlantic salmon, is a characterized ingredient in which specific peptide fractions have been studied for their interaction with metabolic receptors and signaling pathways. This is different from generic fish protein powders or fish collagen, which are not characterized for specific bioactive peptide content.
The primary published study (Currie et al., PMC11595994) is an in-vitro (cell-based, laboratory) study that found specific salmon protein hydrolysate fractions activated GLP-1 and GIP receptors in cell assays. GLP-1 and GIP are incretin hormones involved in satiety signaling, insulin response, and metabolic regulation. These are mechanistically meaningful findings — they show the ingredient interacts with biologically relevant receptor systems. A 42-day randomized, placebo-controlled study in overweight adults has also been conducted on the ProGo® ingredient. Individual results vary, and the research describes the ingredient, not guaranteed product outcomes.
No. ProGo® salmon protein hydrolysate is a different ingredient from fish collagen, fish oil, or omega-3 supplements. Fish collagen primarily supplies glycine, proline, and hydroxyproline for connective tissue support. Omega-3 fish oil supplements supply EPA and DHA fatty acids for cardiovascular and inflammatory pathway support. ProGo® is a hydrolyzed salmon protein that supplies specific short-chain peptide sequences studied for GLP-1, GIP, GLP-2 receptor activity and myostatin pathway interaction. The source (salmon) overlaps, but the biological fractions, manufacturing process, studied mechanisms, and regulatory status are different.
Salmon protein hydrolysate (SPH) is salmon muscle protein that has been broken down enzymatically into short peptide fragments. The biological activity of the resulting peptide fractions depends on the amino acid composition and sequence of the parent protein, which varies by salmon species, diet, growing conditions, and hydrolysis process parameters. ProGo® is produced from Norwegian Atlantic salmon (Salmo salar) using Hofseth BioCare ASA's defined manufacturing process. The published research was conducted on this specific ingredient — not on a generic fish protein. Source and process specificity matter when evaluating bioactive peptide supplements.
FDA New Dietary Ingredient (NDI) status means Hofseth BioCare submitted an NDI notification for ProGo® to the FDA — providing the agency with safety evidence based on the ingredient's history, manufacturing, and available data — and the FDA did not object. This is not the same as FDA approval (the FDA does not approve dietary supplements). NDI status with no objection is the most meaningful US regulatory safety signal available for a supplement ingredient introduced after 1994. It means the ingredient passed the agency's safety review threshold for dietary supplement use.
ProGo® salmon protein hydrolysate carries structure/function claims related to lean-muscle support, connected to research on the ingredient's interaction with myostatin and Activin A signaling pathways. Myostatin is a protein that limits muscle growth; Activin A promotes muscle breakdown. Research on whether specific salmon peptide fractions may support down-regulation of these muscle-limiting signals provides the biological rationale for the lean-muscle preservation claims the FDA has not objected to. For people pursuing weight management, supporting muscle preservation alongside fat loss is an important goal — and this myostatin angle is a distinct pathway beyond the appetite and metabolic signaling research.
In-vitro (cell-based) research tests how an ingredient interacts with cell lines or biological receptors in a laboratory setting. It establishes mechanism — whether an ingredient can activate a specific receptor or trigger a biological signal in a controlled environment. Human clinical studies test whether that mechanism produces measurable outcomes in living people, under controlled conditions. Both types of research are scientifically valuable, but they are not interchangeable. For ProGo®, the GLP-1/GIP receptor activation finding is in-vitro. The 42-day randomized study in overweight adults is human research. Honest supplement science describes both types accurately and does not conflate cell assay findings with guaranteed human outcomes.
triGLP delivers food-grade, NDI-status salmon-derived bioactive peptides supporting GLP-1, GLP-2, GIP, and lean-muscle pathways — in drops, not injections, no prescription needed.
Shop triGLP →Individual results vary.